There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

A new alliance between Sanofi and Google has been launched to improve care in people with type 1 and type 2 diabetes, the latest in a growing number of tie-ups between pharma and technology companies.

“The future in this space is limitless,” said Frenehard. How AI is Enhancing Research and Development at Sanofi AI is being used across the value chain at Sanofi to get treatments to patients ...

Find out more about the collaboration between SandboxAQ and Sanofi, which aims to identify biomarkers using large ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Per the Zacks analyst, amid a volatile macro environment, the company is making significant strides in Business AI initiatives ... are featuring today include Boston Scientific Corp. (BSX), Sanofi ...